Boston Scientific Corporation · NYSE (us_market)
Healthcare · Medical Devices · United States
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-02-10$106.18 RISE2025-04-04$89.70 PEAK2025-06-30$107.41 140d | -15.5% 53d | Missed | Missed | — | — | +19.7% 87d | Missed |
DROP2022-04-20$47.10 RISE2022-06-14$35.24 PEAK2022-09-09$42.94 142d | -25.2% 55d | Missed | Missed | — | — | +21.9% 87d | Missed |
DROP2021-08-02$45.88 RISE2021-11-30$38.07 PEAK2022-02-25$45.10 207d | -17.0% 120d | Missed | Missed | — | — | +18.5% 87d | Missed |
DROP2020-09-02$42.23 RISE2020-11-30$33.15 PEAK2021-02-25$39.67 176d | -21.5% 89d | Missed | Missed | — | — | +19.7% 87d | Missed |
DROP2020-02-19$43.02 RISE2020-06-26$33.28 PEAK2020-09-02$42.23 196d | -22.6% 128d | Missed | Missed | — | — | +26.9% 68d | Missed |
DROP2020-01-09$45.71 RISE2020-03-23$25.83 PEAK2020-06-08$39.11 151d | -43.5% 74d | Missed | Missed | — | — | +51.4% 77d | Missed |
Boston Scientific (BSX) stock has been under pressure after management flagged slowing growth in its Watchman heart implant business, a key contributor to earnings. The company reaffirmed full year guidance and is facing fresh competition in left atrial appendage closure. See our latest analysis for Boston Scientific. The sharp reset in expectations for Watchman growth has coincided with a steep share price selloff, with the stock down 37.1% over three months and the 1 year total shareholder...
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Boston Scientific posted two of the top three Volume-to-Open Interest ratios during Thursday's trading session, a notable signal often associated with heightened market speculation. This unusual options activity suggests the medical devices giant could be a potential acquisition target. Here's a closer look at why.
TFX targets $2.03B in divestiture proceeds; FTC review, tariffs and remediation costs put 2026 timing, margins and leverage in play.
Best Buy downgrade, Dell upgraded: Wall Street's top analyst calls
Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.
Investing.com -- Wolfe Research downgraded Boston Scientific to Peer Perform in a note on Friday, declaring the end of a multiyear bullish thesis on the medical device company after its two key growth engines (pulsed field ablation and the Watchman left atrial appendage closure device) stalled sharply in the first half of 2026.
Sales of a key product line will likely be flat this quarter and next, company management said.
Boston Scientific stock has more questions than answers. Shares of the medical device maker dropped have about 14% this week to about $49 after management said growth of its Watchman product, an implant that reduces the risk of stroke in patients with non-valvular atrial fibrillation (AFib), is slowing. The company stood by its financial guidance, but the market clearly has larger concerns.
Boston Scientific (BSX) concluded the recent trading session at $49.11, signifying a -2.68% move from its prior day's close.
Boston Scientific (BSX) shares fell Wednesday after Chief Executive Mike Mahoney's comments about fl
Investing.com -- Wells Fargo has downgraded Boston Scientific to “Equal Weight” from “Overweight,” citing growing uncertainty around the medical device maker’s two key growth drivers — its electrophysiology (EP) business and the Watchman heart implant franchise.
Boston Scientific (BSX) previously commanded a premium valuation based on its transition toward a high-margin cardiovascular powerhouse, driven by its FARAPULSE Pulsed Field Ablation (PFA) system and WATCHMAN cardiac implant. In Q1 2026, the cardiovascular segment posted a strong 13.5% reported growth. However, intense competition from Medtronic (MDT) and Johnson & Johnson (JNJ) has challenged this hyper-growth thesis. Johnson & Johnson's Varipulse system integrates directly into the dominant CA
Investors have recently become less willing to tolerate compressed margins tied to rising costs and slowing demand.
Boston Scientific Corporation (NYSE:BSX) is one of the best medical technology stocks to buy right now. On May 19, TD Cowen reiterated its Buy rating and $80 price target on Boston Scientific Corporation (NYSE:BSX). TD Cowen constructed its thesis around Boston Scientific’s Fracture IDE study. The study tested the company’s SEISMIQ 4CE Coronary Intravascular Lithotripsy […]
Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.
US equity indexes ground higher amid a slump in crude oil prices as investors parsed ongoing talks t
The medical device maker flags a drop in stand-alone procedures for its Watchman heart implant, hitting its near-term growth forecast.
US equity indexes were higher on Wednesday after a decline in crude oil prices and government bond y
The medical device giant just opened its wallet for a stake in a privately held company with a groundbreaking product.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BSX | -14.50% | -36.62% | -49.33% | -54.10% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -17.46% | -30.90% | -45.89% | -66.79% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 74.23M | $4.66B | 0.25% | Trimmed-23.8% | 2026-03-31 |
| StateStreet | passive | 67.99M | $4.27B | 0.15% | Added+3.3% | 2026-03-31 |
| DEShaw | quant | 24.31M | $1.53B | 0.92% | Added+116.1% | 2026-03-31 |
| Wellington | fundamental | 18.83M | $1.18B | 0.22% | Added+94.0% | 2026-03-31 |
| TwoSigma | quant | 9.41M | $590.55M | 0.48% | Added+280.8% | 2026-03-31 |
| CapResearch | fundamental | 7.08M | $444.33M | 0.07% | Unchanged | 2026-03-31 |
| Citadel | multi-strat | 3.69M | $231.38M | 0.30% | Added+51.5% | 2026-03-31 |
| RenTech | quant | 3.15M | $197.79M | 0.31% | Added+32.3% | 2026-03-31 |
| LonePine | growth | 104.7K | $6.57M | 0.05% | Trimmed-48.1% | 2026-03-31 |
| Bridgewater | macro | 77.0K | $4.83M | 0.02% | Trimmed-17.9% | 2026-03-31 |
| TRowePrice | fundamental | 7.87M | $494.05K | 0.06% | Added+5.6% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-21 | Habiger David C | Director | P Open-market purchase | 2,250 | $55.92 | +$125.8K |
| 2026-05-21 | Habiger David C | Director | P Open-market purchase | 2,200 | $56.95 | +$125.3K |
| 2026-05-21 | LUDWIG EDWARD J | Director | P Open-market purchase | 3,580 | $56.68 | +$202.9K |
| 2026-05-21 | Pegus Cheryl | Director | P Open-market purchase | 1,770 | $56.49 | +$100.0K |
| 2026-05-11 | Habiger David C | Director | A Grant / award | 3,800 | — | +$0 |
| 2026-05-11 | LUDWIG EDWARD J | Director | A Grant / award | 3,800 | — | +$0 |
| 2026-05-11 | Mega Jessica L | Director | A Grant / award | 3,800 | — | +$0 |
| 2026-05-11 | Morano Susan E | Director | A Grant / award | 1,281 | — | +$0 |
| 2026-05-11 | Morano Susan E | Director | A Grant / award | 3,800 | — | +$0 |
| 2026-05-11 | Pegus Cheryl | Director | A Grant / award(deriv) | 1,281 | — | +$0 |
| 2026-05-11 | Pegus Cheryl | Director | A Grant / award(deriv) | 3,800 | — | +$0 |
| 2026-05-11 | Smith Cathy R | Director | A Grant / award(deriv) | 2,209 | — | +$0 |
| 2026-05-11 | Smith Cathy R | Director | A Grant / award(deriv) | 3,800 | — | +$0 |
| 2026-05-11 | Weber Christophe Pierre | Director | A Grant / award(deriv) | 2,660 | — | +$0 |
| 2026-05-11 | Weber Christophe Pierre | Director | A Grant / award | 1,140 | — | +$0 |
| 2026-05-11 | Weber Christophe Pierre | Director | A Grant / award | 1,767 | — | +$0 |
| 2026-05-11 | WICHMANN DAVID S | Director | A Grant / award | 3,800 | — | +$0 |
| 2026-05-11 | Zane Ellen M | Director | A Grant / award | 3,800 | — | +$0 |
| 2026-05-04 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | M Option exercise(deriv) | 2,102 | — | +$0 |
| 2026-05-04 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | F Tax withholding | 1,007 | $56.50 | −$56.9K |
| 2026-05-04 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | M Option exercise | 2,102 | — | +$0 |
| 2026-05-04 | O'Connor Padraig Andrew | EVP, Global Operations | M Option exercise(deriv) | 1,802 | — | +$0 |
| 2026-05-04 | O'Connor Padraig Andrew | EVP, Global Operations | F Tax withholding | 872 | $56.50 | −$49.3K |
| 2026-05-04 | O'Connor Padraig Andrew | EVP, Global Operations | M Option exercise | 1,802 | — | +$0 |
| 2026-03-04 | Smith Cathy R | Director | A Grant / award(deriv) | 323 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-29upcoming | 0.83 | — | — |
| 2026-04-22 | 0.79 | 0.80 | +1.62% |
| 2026-02-04 | 0.78 | 0.80 | +2.43% |
| 2025-10-22 | 0.71 | 0.75 | +5.09% |
| 2025-07-23 | 0.73 | 0.75 | +3.42% |
| 2025-04-23 | 0.67 | 0.75 | +11.52% |
| 2025-02-05 | 0.66 | 0.70 | +6.57% |
| 2024-10-23 | 0.59 | 0.63 | +7.05% |
| 2024-07-24 | 0.58 | 0.62 | +6.51% |
| 2024-04-24 | 0.51 | 0.56 | +9.14% |
| 2024-01-31 | 0.51 | 0.55 | +7.33% |
| 2023-10-26 | 0.48 | 0.50 | +4.72% |
| 2023-07-27 | 0.49 | 0.53 | +8.15% |
| 2023-04-26 | 0.43 | 0.47 | +8.60% |
| 2023-02-01 | 0.47 | 0.45 | -4.64% |
| 2022-10-26 | 0.44 | 0.43 | -2.57% |